公开(公告)号：US20180303901A1

公开(公告)日：2018-10-25

申请号：US15976534

申请日：2018-05-10

Applicant: Utpal Pajvani ,  Jan Kitajewski

Inventor： Utpal Pajvani ,  Jan Kitajewski

IPC: A61K38/17 ,  C07K14/705 ,  A61K45/06 ,  A61K48/00

CPC classification number: A61K38/177 ,  A61K45/06 ,  A61K48/00 ,  C07K14/705 ,  C07K2319/30 ,  A61K2300/00

Abstract: The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease.The present invention provides a composition comprising a pharmaceutically acceptable carrier and an amount of a Notch decoy protein or Jagged inhibitor effective to treat a fatty liver disease.The present invention provides a package comprising: (a) the pharmaceutical composition of the invention; and (b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.

公开(公告)号：US20160030513A1

公开(公告)日：2016-02-04

申请号：US14814407

申请日：2015-07-30

Applicant: Utpal Pajvani ,  Jan Kitajewski

Inventor： Utpal Pajvani ,  Jan Kitajewski

IPC: A61K38/17 ,  A61K45/06

CPC classification number: A61K38/177 ,  A61K45/06 ,  A61K48/00 ,  C07K14/705 ,  C07K2319/30 ,  A61K2300/00

Abstract: The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease.The present invention provides a composition comprising a pharmaceutically acceptable carrier and an amount of a Notch decoy protein or Jagged inhibitor effective to treat a fatty liver disease.The present invention provides a package comprising:(a) the pharmaceutical composition of the invention and (b) instructions for using the pharmaceutical composition of step (a) to treat the fatty liver disease.

Abstract translation: 本发明提供了治疗患有脂肪肝疾病的受试者的方法，其包括以有效治疗受试者的脂肪肝疾病的量向受试者施用Notch诱饵蛋白或锯齿状抑制剂。 本发明提供了包含药学上可接受的载体和一定量的有效治疗脂肪肝疾病的Notch诱饵蛋白或锯齿状抑制剂的组合物。 本发明提供一种包装，其包含：（a）本发明的药物组合物和（b）使用步骤（a）的药物组合物治疗脂肪肝疾病的说明书。

公开(公告)号：US20100273990A1

公开(公告)日：2010-10-28

申请号：US12657573

申请日：2010-01-21

Applicant: Jan Kitajewski ,  Carrie Shawber ,  Yasuhiro Funahashi

Inventor： Jan Kitajewski ,  Carrie Shawber ,  Yasuhiro Funahashi

IPC: C07K16/46

CPC classification number: A61K48/00 ,  A61K9/0019 ,  A61K38/00 ,  C07K14/705 ,  C07K2319/30 ,  C07K2319/32

Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.

公开(公告)号：US20160115217A1

公开(公告)日：2016-04-28

申请号：US14844642

申请日：2015-09-03

Applicant: Jan Kitajewski ,  Carrie Shawber

Inventor： Jan Kitajewski ,  Carrie Shawber

IPC: C07K14/705

CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/30

Abstract: This invention provides a fusion protein comprising a signal peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.

Abstract translation: 本发明提供了包含信号肽，人Notch受体蛋白质的细胞外结构域和与其结合的抗体的Fc部分的融合蛋白质。 本发明还提供了治疗患有肿瘤的受试者的方法，用于抑制受试者血管发生的方法，用于治疗患有卵巢癌的受试者的方法，以及用于治疗具有代谢紊乱的受试者的方法，所述方法包括对所述受试者施用 上述融合蛋白有效治疗受试者的量。 本发明还提供了上述融合蛋白用于制备用于治疗患有肿瘤的受试者，用于抑制受试者的血管生成，用于治疗患有卵巢癌的受试者的药物组合物的用途，以及用于治疗具有代谢 紊乱。

公开(公告)号：US20150329615A1

公开(公告)日：2015-11-19

申请号：US14668525

申请日：2015-03-25

Applicant: Jan Kitajewski ,  Carrie Shawber ,  Yasuhiro Funahashi

Inventor： Jan Kitajewski ,  Carrie Shawber ,  Yasuhiro Funahashi

IPC: C07K14/705

CPC classification number: A61K48/00 ,  A61K9/0019 ,  A61K38/00 ,  C07K14/705 ,  C07K2319/30 ,  C07K2319/32

Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.

Abstract translation: 本发明提供了治疗患有肿瘤的受试者的方法和用于抑制受试者血管生成的方法，所述方法包括向受试者施用有效量的包含Notch受体蛋白的细胞外结构域的物质组合物， 生命增加部分。 本发明还提供了包含Notch4受体蛋白的细胞外结构域的物质组合物，其可操作地附着于半衰期增加的部分。 本发明还提供了一种制造品。 最后，本发明提供了可复制载体，其编码包含可操作地附着于半衰期增加部分的Notch受体蛋白的细胞外结构域的多肽，包含该可复制载体的宿主载体系统和产生该多肽的方法。

公开(公告)号：US09127085B2

公开(公告)日：2015-09-08

申请号：US12733329

申请日：2008-08-22

Applicant: Jan Kitajewski ,  Carrie Shawber

Inventor： Jan Kitajewski ,  Carrie Shawber

IPC: C07K14/705 ,  A61K38/00

CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/30

Abstract: This invention provides a fusion protein comprising a single peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.

Abstract translation: 本发明提供了包含单个肽，人类Notch受体蛋白质的细胞外结构域和与之结合的抗体的Fc部分的融合蛋白质。 本发明还提供了治疗患有肿瘤的受试者的方法，用于抑制受试者血管发生的方法，用于治疗患有卵巢癌的受试者的方法，以及用于治疗具有代谢紊乱的受试者的方法，所述方法包括对所述受试者施用 上述融合蛋白有效治疗受试者的量。 本发明还提供了上述融合蛋白用于制备用于治疗患有肿瘤的受试者，用于抑制受试者的血管生成，用于治疗患有卵巢癌的受试者的药物组合物的用途，以及用于治疗具有代谢 紊乱。

公开(公告)号：US09738708B2

公开(公告)日：2017-08-22

申请号：US14349975

申请日：2012-10-04

Applicant: Jan Kitajewski ,  Carrie Shawber ,  Thaned Kangsamaksin

Inventor： Jan Kitajewski ,  Carrie Shawber ,  Thaned Kangsamaksin

IPC: C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K19/00 ,  A61K38/17 ,  C07K16/28 ,  C07K16/18

CPC classification number: C07K16/18 ,  A61K38/177 ,  A61K38/1774 ,  A61K38/179 ,  A61K38/1793 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/283 ,  C07K19/00 ,  C07K2319/30 ,  C07K2319/32

Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of BGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AND), diabetic retinopathy and cancer using the fusion proteins described herein.

公开(公告)号：US09475855B2

公开(公告)日：2016-10-25

申请号：US13060254

申请日：2009-08-21

Applicant: Jan Kitajewski ,  Carrie Shawber

Inventor： Jan Kitajewski ,  Carrie Shawber

IPC: C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/46 ,  C07K19/00 ,  C07K14/485 ,  A61K38/17 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K14/485 ,  A61K38/177 ,  A61K38/179 ,  A61K38/1793 ,  A61K39/395 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/46 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30

Abstract: This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.

Abstract translation: 本发明提供了融合蛋白，其包含信号肽EGF重复人Notch3受体蛋白的细胞外结构域的1-X，其中X为12至34的任何整数，以及与其结合的抗体的Fc部分。 本发明还提供了治疗患有肿瘤的受试者的方法，用于抑制受试者血管发生的方法，用于治疗患有卵巢癌的受试者的方法，以及用于治疗具有代谢紊乱的受试者的方法，所述方法包括对所述受试者施用 上述融合蛋白有效治疗受试者的量。 本发明还提供了上述融合蛋白用于制备用于治疗患有肿瘤的受试者，用于抑制受试者的血管生成，用于治疗患有卵巢癌的受试者的药物组合物的用途，以及用于治疗具有代谢 紊乱。

公开(公告)号：US20110223183A1

公开(公告)日：2011-09-15

申请号：US13060254

申请日：2009-08-21

Applicant: Jan Kitajewski ,  Carrie Shawber

Inventor： Jan Kitajewski ,  Carrie Shawber

IPC: A61K39/395 ,  C07K19/00 ,  A61P35/00 ,  A61P35/04 ,  A61P3/00

CPC classification number: C07K14/485 ,  A61K38/177 ,  A61K38/179 ,  A61K38/1793 ,  A61K39/395 ,  A61K2039/505 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/46 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30

Abstract: This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.

Abstract translation: 本发明提供了融合蛋白，其包含信号肽EGF重复人Notch3受体蛋白的细胞外结构域的1-X，其中X为12至34的任何整数，以及与其结合的抗体的Fc部分。 本发明还提供了治疗患有肿瘤的受试者的方法，用于抑制受试者血管发生的方法，用于治疗患有卵巢癌的受试者的方法，以及用于治疗具有代谢紊乱的受试者的方法，所述方法包括对所述受试者施用 上述融合蛋白有效治疗受试者的量。 本发明还提供了上述融合蛋白用于制备用于治疗患有肿瘤的受试者，用于抑制受试者的血管生成，用于治疗患有卵巢癌的受试者的药物组合物的用途，以及用于治疗具有代谢 紊乱。

公开(公告)号：US20170306006A1

公开(公告)日：2017-10-26

申请号：US15641712

申请日：2017-07-05

Applicant: Jan Kitajewski ,  Carrie Shawber ,  Thaned Kangsamaksin

Inventor： Jan Kitajewski ,  Carrie Shawber ,  Thaned Kangsamaksin

IPC: C07K16/18 ,  C07K14/705 ,  A61K38/17 ,  C07K19/00 ,  C07K14/71 ,  C07K14/715 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K38/177 ,  A61K38/1774 ,  A61K38/179 ,  A61K38/1793 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K16/283 ,  C07K19/00 ,  C07K2319/30 ,  C07K2319/32

Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.